BiotechTube

APX005M treatment for recurrent or refractory primary malignant CNS tumor patients + APX005M treatment for newly diagnosed DIPG patients

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioblastoma Multiforme

Conditions

Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS), Diffuse Intrinsic Pontine Gliomas (DIPG), Medulloblastoma

Trial Timeline

Mar 1, 2018 → Jun 30, 2026

NCT ID
NCT03389802

About APX005M treatment for recurrent or refractory primary malignant CNS tumor patients + APX005M treatment for newly diagnosed DIPG patients

APX005M treatment for recurrent or refractory primary malignant CNS tumor patients + APX005M treatment for newly diagnosed DIPG patients is a phase 1 stage product being developed by Pyxis Oncology for Glioblastoma Multiforme. The current trial status is active. This product is registered under clinical trial identifier NCT03389802. Target conditions include Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS).

What happened to similar drugs?

1 of 18 similar drugs in Glioblastoma Multiforme were approved

Approved (1) Terminated (1) Active (16)
✅TemozolomideMerckApproved
🔄enzastaurin + lomustineEli LillyPhase 3
🔄DSP-7888 Dosing Emulsion + BevacizumabSumitomo PharmaPhase 3
🔄Temozolomide + Depatuxizumab mafodotin + Placebo for ABT-414AbbViePhase 3
❌Steroid eye drops + Vasoconstrictor eye drops + Ophthalmic steroid ointment + Depatuxizumab mafodotin + TemozolomideAbbViePhase 3
🔄Cediranib + Cediranib + Lomustine Chemotherapy + Placebo CediranibAstraZenecaPhase 3
🔄Cilengitide + TemozolomideMerckPhase 3

Hype Score Breakdown

Clinical
6
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03389802Phase 1Active

Competing Products

20 competing products in Glioblastoma Multiforme

See all competitors
ProductCompanyStageHype Score
TemferonGenenta SciencePhase 1/2
26
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
32
PLX3397Daiichi SankyoPhase 2
27
ASP8374 + cemiplimabAstellas PharmaPhase 1
29
Nimotuzumab + TemozolomideSun PharmaceuticalPhase 2
35
Gliadel + Avastin + TemodarEisaiPhase 2
27
BCNU Wafer + Irinotecan + BevacizumabEisaiPhase 1/2
24
KHK2455Kyowa KirinPre-clinical
26
olaratumab + ramucirumabEli LillyPhase 2
35
enzastaurin + temozolomideEli LillyPhase 1/2
32
enzastaurin + bevacizumab + Enzyme-inducing antiepileptic drugs (EIAED) + Non-enzyme inducing antiepileptic drugs (NEIAED)Eli LillyPhase 2
35
Temozolomide + Neratinib + QBS10072S + Abemaciclib + CC-115Eli LillyPhase 2
42
AbemaciclibEli LillyPhase 2
39
Enzastaurin 500 milligram (mg) Once Daily (QD) + Enzastaurin 250 mg Twice Daily (BID)Eli LillyPhase 2
35
Abemaciclib + LY3214996Eli LillyPhase 1
29
enzastaurin + lomustineEli LillyPhase 3
40
Galunisertib + Lomustine + PlaceboEli LillyPhase 2
35
DSP-7888 Dosing Emulsion + BevacizumabSumitomo PharmaPhase 3
40
DSP-7888Sumitomo PharmaPhase 1/2
32
BBI608 + TemozolomideSumitomo PharmaPhase 1/2
32